Cargando…

Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer

Treatment options for triple-negative breast cancer (TNBC) are limited due to the lack of efficient targeted therapies, frequently resulting in recurrence and metastatic disease. Accumulating evidence suggests that a small population of cancer stem-like cells (CSLCs) is responsible for tumor recurre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brisard, Daphne, Eckerdt, Frank, Marsh, Lindsey A., Blyth, Gavin T., Jain, Sarika, Cristofanilli, Massimo, Horiuchi, Dai, Platanias, Leonidas C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324664/ https://www.ncbi.nlm.nih.gov/pubmed/30647871 http://dx.doi.org/10.18632/oncotarget.26468

Ejemplares similares

Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma
por: Eckerdt, Frank, et al.
Publicado: (2019)

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
por: Lücking, Ulrich, et al.
Publicado: (2017)

Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance
por: Eckerdt, Frank, et al.
Publicado: (2023)

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-κB Signaling Pathway
por: Ni, Weiyu, et al.
Publicado: (2020)

In vitro antineoplastic activity in triple-negative breast cancer cell line and in vivo
por: Madeira, Klesia, et al.
Publicado: (2014)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye, Jun, et al.
Publicado: (2016)

HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma
por: Bell, Jonathan B., et al.
Publicado: (2018)

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
por: Rao, Shreyas S., et al.
Publicado: (2017)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Regulation of IFNα-induced expression of the short ACE2 isoform by ULK1
por: Perez, Ricardo E., et al.
Publicado: (2022)

Inhibitory effects of SEL201 in acute myeloid leukemia
por: Kosciuczuk, Ewa M., et al.
Publicado: (2019)

CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
por: Dai, Meiou, et al.
Publicado: (2016)

Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells
por: Eckerdt, Frank, et al.
Publicado: (2014)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
por: Ge, Jennifer Y., et al.
Publicado: (2020)

CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1
por: Li, Xiao, et al.
Publicado: (2022)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
por: Saleh, Lubaid, et al.
Publicado: (2021)

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
por: Beykou, Melina, et al.
Publicado: (2022)

Landscape of circulating tumour DNA in metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2020)

TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients
por: Fernandez, Sandra V, et al.
Publicado: (2014)

Targeting Cytokines and Their Pathways for the Treatment of Cancer
por: Heimberger, Amy B., et al.
Publicado: (2023)

In Vitro and In Vivo Relevant Antineoplastic Activity of Platinum(II) Complexes toward Triple-Negative MDA-MB-231 Breast Cancer Cell Line
por: Maciel, Leide Laura Figueiredo, et al.
Publicado: (2022)

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2019)

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
por: Fassl, Anne, et al.
Publicado: (2020)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer
por: Liang, Hanzhi, et al.
Publicado: (2022)

CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
por: Cheung, Anthony, et al.
Publicado: (2022)

Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis
por: Han, Zhitao, et al.
Publicado: (2023)

Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition
por: Iqbal, Asneha, et al.
Publicado: (2016)

Human SLFN5 is a Transcriptional Co-repressor of STAT1-Mediated Interferon Responses and Promotes the Malignant Phenotype in Glioblastoma
por: Arslan, Ahmet Dirim, et al.
Publicado: (2017)

ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer
por: Li, Dong, et al.
Publicado: (2023)

TGF-β/activin signaling promotes CDK7 inhibitor resistance in triple-negative breast cancer cells through upregulation of multidrug transporters
por: Webb, Bryan M., et al.
Publicado: (2021)

Evidence for tankyrases as antineoplastic targets in lung cancer
por: Busch, Alexander M, et al.
Publicado: (2013)

Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients
por: van Dorst, Daan C.H., et al.
Publicado: (2021)

EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer
por: Liu, Xia, et al.
Publicado: (2021)

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Nie, Lei, et al.
Publicado: (2019)

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
por: Peng, Jingyu, et al.
Publicado: (2021)

CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer
por: Sang, Xiaoye, et al.
Publicado: (2022)

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
por: Varella, Leticia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vkrib3hrdvq8mfunv47dauacl6